ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona

Gilead Sciences at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Gilead Sciences takes part in 3 sessions at ESMO 2026 in Madrid, and exhibits at Booth 8063. Its sessions focus on antibody-drug conjugates in breast and gynaecological cancers and on evidence for lung cancer treatment decisions. They cover treatment strategies for advanced triple-negative breast cancer and using real-world data to compare outcomes.

OrganizationESMO 2026 Attendance
Large pharmaExhibitor
US biopharmaceutical company whose oncology unit, with cell-therapy arm Kite, markets antibody-drug conjugates and CAR T therapies.
Booth
Exhibiting at Booth 8063 · Gilead and Kite Oncology
Poster
Fri Oct 23
13:00–15:00
Extending RWD–based external control arms from hematologic to lung malignancies for clinical and regulatory decision-making
ePoster session 25
Haematological malignanciesLung & thoracic cancers
Satellite
Sun Oct 25
18:30–20:00
Gilead and Kite Oncology - The ADC Evolution in Breast and Gynaecologic Cancers: Foundation, Advancement, Future Directions
Sponsored session · with Latin American Cooperative Oncology Group
Breast cancerGynaecological cancers

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Gilead Sciences

Tell us what you sell and we’ll find the people at Gilead Sciences most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction